Skip to main content

Table 2 Case review on rhabdomyolysis during hematopoietic stem cell transplantation

From: Acute rhabdomyolysis in hepatitis-associated aplastic anemia patient undergoing allogeneic hematopoietic stem-cell transplantation: case report and literature review

Case

Study

Years/gender

Primary disease

Conditioning regimen

Transplant

Time

Suspected cause

Symptom

Creatine kinase

AKI

Therapy

Fate

1

Volin, et al., 199011

27/M

CML

Cyclophosphamide, TBI

MSDT

 + 3 month

CsA, corticosteroids, fluconazole

Grand mal seizure, bilateral lower extremity weakness, pain, dark red urine

81,000 U/L

Yes

Peritoneal dialysis

Died

2

Maruyama, et al.,199412

17/F

Ki-1 lymphoma

Melphalan, etoposide and TBI

PBSCT

 + 23 day

CMV infection

Severe muscle weakness, muscle pain

110 mU/mL (< 25 mU/mL)

Yes (Cr = 4.2 mg/dl)

Hydration, alkalization

Survive

3

Hoshi, et al.,199913

38/M

CC

Ifosfamide, carboplatin, etoposide

Auto-HSCT

0 day

HDC, pretreatment renal dysfunction, ifosfamide, sedatives

Dyspnea, hemoptysis, dark red urine

6150 IU/L

Yes

Hemodialysis

Died (respiratory failure)

4

Pugliese, et al.,200014

Unknown

Breast cancer

Cyclophosphamide

Auto-HSCT

 + 7 day

Vancomycin

Severe muscle weakness

1756 U/L

No

Hydration, alkalization

Survive

5

Rossi, et al.,200015

16/M

ATL

TBI, etoposide, cyclophosphamide

MSDT

 + 11 day

ABCD

Muscular hypertonus, trismus, severe muscular pain

21,730 U/L

No

Intensive care unit

Survive

6

Shima, et al.,200216

47/F

ATLL

TBI, cyclophosphamide

NO

Pre-transplant period

High-dose cyclophosphamide

Generalized convulsions, muscle fatigue, severe acidosis

34,863 IU/L

No

Hydration, alkalization

Survive

7

Tong, et al.,200517

66/M

MM

TBI, cyclophosphamide

Auto-HSCT, MSDT

 + 22 day

CsA, simvastatin

Bilateral lower extremity weakness, pain

29,253 U/L

Yes (Cr = 2 mg/dl)

Hydration, alkalization

Survive

8

Vives, et al.,200818

54/M

AML

Fludarabine, busulfan

MSDT

 + 1 month

Simvastatin, CsA, risperidone

Pelvic muscle weakness, severe muscular pain

88 370 U/L

Yes (Cr = 4.81 mg/dl)

Hydration, alkalization

Survive

9

Jiang, et al.,201619

41/F

CML

Busulfan, cyclophosphamide

MSDT

 + 55 day

Infection, GVHD, metabolic disorders, CsA, methylprednisolone

Anasarca and muscle tenderness

1614 μg/L(25–200 μg/L)

Yes

Unknown

Died

10

Sokolova, et al.,201720

21/M

GCT

Unknown

Auto-HSCT

 + 12 day

Paclitaxel, ifosfamide, carboplatin, etoposide

Bilateral leg pain

30,841 IU/L

No

Hydration, alkalization

Survive

11

Our case

55/M

HAAA

Fludarabine, ATG, cyclophosphamide

Haplo-HSCT

 + 7 day

Gene mutation, muscle strain, Infection, TMP/SMX, atorvastatin

Muscle pain, dark urine, swelling of the left thigh

852 U/L

Yes

Hydration, alkalization

Died

  1. CML chronic myeloid leukemia, CC choriocarcinoma, ATL acute T-cell lymphoblastic leukemia, ATLL adult T-cell leukemia/lymphoma, MM multiple myeloma, AML acute myelogenous leukemia, GCT germ cell tumor, HAAA hepatitis-associated aplastic anemia, MSDT matched sibling donor transplantation, PBSCT peripheral blood stem cell transplantation, Auto-HSCT autologous hematopoietic stem cell transplantation, Haplo-HSCT haploidentical hematopoietic stem cell transplantation, TBI total body irradiation, HDC high-dose chemotherapy, CsA cyclosporine A, CMV cytomegalovirus, ABCD amphotericin B colloidal dispersion, AKI acute kidney injury